Actinic keratosis and imiquimod: a review of novel carriers and patents

References

• Dubreuilh WA. Des hyperkeratoses circonscrites (1). Ann Dermatol Venereol. 1896;27:1158–1204.
   Google Scholar
• Yantsos VA, Conrad N, Zabawski E, et al. Incipient intraepidermal cutaneous squamous cell carcinoma: a proposal for reclassifying and grading solar (actinic) keratoses. Semin Cutan Med Surg. 1999;18(1):3–14.
   PubMed Web of Science ®Google Scholar
• Sutton RLJ. Early epidermal neoplasia: description and interpretation—the theory of mutation in the origin of cancer. Arch Dermatol Syphil. 1938;37:737–780.
   Google Scholar
• Heaphy MR, Ackerman AB. The nature of solar keratosis: A critical review in historical perspective. J Am Acad Dermatol. 2000;43:138–150.
   PubMed Web of Science ®Google Scholar
• Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol. 2006;155(1):9–22.
   PubMed Web of Science ®Google Scholar
• LeBoit PE, Burg G, Weedon D, et al. editors. World health organization classification of skin tumours. Pathology and genetics skin tumours. Lyon France: IARC Press; 2006.
   Google Scholar
• Feldman SR, Fleischer ABJ, McConnell C. Most common dermatologic problems identified by internists, 1990–1994. Arch Intern Med. 1998;158:649–655.
   Google Scholar
• Marks R, Jolley D, Dorevitch AP, et al. The incidence of non-melanocytic skin cancers in an Australian population: results of a five-year prospective study. Med J Aust. 1989;150(9):475–478.
   PubMed Web of Science ®Google Scholar
• Rossi R, Mori M, Lotti T. Actinic keratosis. Int J Dermatol. 2007;46:895–904.
   PubMed Web of Science ®Google Scholar
• de Berker D, McGregor JM, Hughes BR. Guidelines for the management of actinic keratoses. Br J Dermatol. 2007;156:222–230.
   PubMed Web of Science ®Google Scholar
• Flohil SC, van der Leest RJ, Dowlatshahi EA, et al. Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam study. J Invest Dermatol. 2013;133(8):1971–1978.
   PubMed Web of Science ®Google Scholar
• Dodson JM, DeSpain J, Hewett JE, et al. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol. 1991;127:1029–1031.
   PubMed Web of Science ®Google Scholar
• Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42(1 Pt 2):4–7.
   PubMed Web of Science ®Google Scholar
• Hsieh CF, Chiang YT, Chiu HY, et al. A nationwide cohort study of actinic keratosis in Taiwan. Int J Gerontol. 2016;10:218–222.
   Web of Science ®Google Scholar
• Sajad P, Hassan I, Reshi R, et al. Pattern of skin tumours in Kashmir valley of north India: A hospital based clinicopathological study. IJIRR. 2015;2(2):376–381.
   Google Scholar
• LeBoit PE, Burg G, Weedon D, et al. editors. World health organization classification of skin tumours. Lyon (France): IARCPress; 2006.
   Google Scholar
• Roewert-Huber J, Stockfleth E, Pathology KH. Pathobiology of actinic (solar) keratosis – an update. Br J Dermatol. 2007;157(Suppl. 2):18–20.
   PubMedGoogle Scholar
• Didona D, Paolino G, Bottoni U, et al. Non melanoma skin cancer pathogenesis overview. Biomedicines. 2018;6(1):6.
   PubMed Web of Science ®Google Scholar
• Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol. 1994;131(4):455–464.
   PubMed Web of Science ®Google Scholar
• Berking C, Takemoto R, Binder RL, et al. Photocarcinogenesis in human adult skin grafts. Carcinogenesis. 2002;23:181–187.
   PubMed Web of Science ®Google Scholar
• Butani A, Arbesfeld DM, Schwartz RACPS. Premalignant and early squamous cell carcinoma. Clin Plast Surg. 2005;32:223–235.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Abernethy ML, Kulp-Shorten C, et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol. 1991;24(5 Pt 1):738–743.
   PubMed Web of Science ®Google Scholar
• Camacho MF. Actinic keratosis. In: Katsambas AD, Lotti TM, editors. European handbook of dermatological treatments. 2nd ed. Berlin, Heidelberg, New York: Springer-Verlag; 2003. p. 10–15.
   Google Scholar
• Sotiriou E, Apalla Z, Maliamani F, et al. Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities. J Eur Acad Dermatol Venereol. 2009;2009(23):9.
   Google Scholar
• Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157(Suppl 2):34–40.
   PubMed Web of Science ®Google Scholar
• Kose O, Koc E, Erbil AH, et al. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis. J Dermatolog Treat. 2008;19(3):159–163.
   PubMed Web of Science ®Google Scholar
• Akarsu S, Aktan S, Atahan A, et al. Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses. Clin Exp Dermatol. 2011;36(5):479–484.
   PubMed Web of Science ®Google Scholar
• Vale SM, Hill D, Feldman SR. Pharmacoeconomic considerations in treating actinic keratosis: an update. Pharmacoeconomics. 2017;35(2):177–190.
   PubMed Web of Science ®Google Scholar
• Astorino S, Astorre P, Pasquini P, et al. Imiquimod 5% cream in occlusion, for the treatment of lentigo maligna: A new scheme of short cycles and the need for clinical trials. Dermatol Ther. 2018;e12757. doi:10.1111/dth.12757.
   PubMed Web of Science ®Google Scholar
• Biju SS, Talegaonkar S, Mishra PR, et al. Vesicular systems: an overview. Indian J Pharm Sci. 2006;68(2):141–153.
   Google Scholar
• Bulbake U, Doppalapudi S, Kommineni N, et al. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):E12.
   PubMed Web of Science ®Google Scholar
• Budavari S, editor. The merck index. An encyclopedia of chemicals, drugs, and biologicals. 11 ed. Rahway, NJ, USA: Merck & Co., Inc.; 1989.
   Google Scholar
• Sweetman SC, editor Martindale the complete drug reference. Vol. 37. London: Pharmaceutical Press; 2011.
   Google Scholar
• Rizwan SB, McBurney WT, Young K, et al. Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses. J Control Release. 2013;165(1):16–21.
   PubMed Web of Science ®Google Scholar
• Vicente S, Peleteiro M, Diaz-Freitas B, et al. Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: a needle-free vaccination strategy. J Control Release. 2013;172(3):773–781.
   PubMed Web of Science ®Google Scholar
• Sinko PJ. Complexation and protein binding. In: Troy D, editor. Physical pharnacy and pharmaceutical sciences. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 267–297.
   Google Scholar
• Shin WJ, Noh HJ, Noh YW, et al. Hyaluronic acid-supported combination of water insoluble immunostimulatory compounds for anti-cancer immunotherapy. Carbohydr Polym. 2017;155:1–10.
   PubMed Web of Science ®Google Scholar
• Rehman K, Aluwi MF, Rullah K, et al. Probing the effects of fish oil on the delivery and inflammation-inducing potential of imiquimod. Int J Pharm. 2015;490(1–2):131–141.
   PubMedGoogle Scholar
• Rhee GJ, Woo JS, Hwang SJ, et al. Topical oleo-hydrogel preparation of ketoprofen with enhanced skin permeability. Drug Dev Ind Pharm. 1999;25(6):717–726.
   PubMed Web of Science ®Google Scholar
• Rehman K, Zulfakar MH. Recent advances in gel technologies for topical and transdermal drug delivery. Drug Dev Ind Pharm. 2014;40(4):433–440.
   PubMed Web of Science ®Google Scholar
• Rehman K, Zulfakar MH. Novel fish oil-based bigel system for controlled drug delivery and its influence on immunomodulatory activity of imiquimod against skin cancer. Pharm Res. 2017;34(1):36–48.
   PubMed Web of Science ®Google Scholar
• Stein P, Gogoll K, Tenzer S, et al. Efficacy of imiquimod-based transcutaneous immunization using a nano-dispersed emulsion gel formulation. PLoS One. 2014;9(7):e102664.
   PubMed Web of Science ®Google Scholar
• Makhmalzade BS, Chavoshy F. Polymeric micelles as cutaneous drug delivery system in normal skin and dermatological disorders. J Adv Pharm Technol Res. 2018;9(1):2–8.
   PubMed Web of Science ®Google Scholar
• Lapteva M, Kalia YN. Related topic: encapsulation technologies—polymeric micelles in dermal and transdermal delivery. In: Sugibayashi K, editor. Skin permeation and disposition of therapeutic and cosmeceutical compounds. Tokyo: Springer; 2017. p. 143–152.
   Google Scholar
• Jiménez-Sánchez G, Pavot V, Chane-Haong C, et al. Preparation and in vitro evaluation of imiquimod loaded polylactide-based micelles as potential vaccine adjuvants. Pharm Res. 2015;32(1):311–320.
   PubMed Web of Science ®Google Scholar
• Lin W, Hanson S, Han W, et al. Well-defined star polymers for co-delivery of plasmid DNA and imiquimod to dendritic cells. Acta Biomater. 2017;15(48):378–389.
   Google Scholar
• Madhav NVS, Kala S. Review on microparticulate drug delivery system. Int J Pharmtech Res. 2011;3:1242–1254.
   Google Scholar
• Padalha NA, Shahi RS, Mahesh W. Micro particles: an approach for betterment of drug delivery system. Int J Pharm Res Dev. 2011;3:99–115.
   Google Scholar
• Kohane DS. Microparticles and nanoparticles for drug delivery. Biotechnol Bioeng. 2007;96(2):203–209.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Tsai PC, Ramezanli T, et al. Polymeric nanoparticles-based topical delivery systems for the treatment of dermatological diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013;5(3):205–218.
   PubMed Web of Science ®Google Scholar
• Bachelder EM, Beaudette TT, Broaders KE, et al. In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants. Mol Pharm. 2010;7(3):826–835.
   PubMed Web of Science ®Google Scholar
• Primard C, Poecheim J, Heuking S, et al. Multifunctional PLGA-based nanoparticles encapsulating simultaneously hydrophilic antigen and hydrophobic immunomodulator for mucosal immunization. Mol Pharm. 2013;10(8):2996–3004.
   PubMed Web of Science ®Google Scholar
• Dias MF, Figueiredo BCP, Teixeira-Neto J, et al. In vivo evaluation of antitumoral and antiangiogenic effect of imiquimod-loaded polymeric nanoparticles. Biomed Pharmacother. 2018;103:1107–1114.
   PubMed Web of Science ®Google Scholar
• Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm. 2010;385(1–2):113–142.
   PubMed Web of Science ®Google Scholar
• Müller RH, Petersen RD, Hommoss A, et al. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev. 2007;59(6):522–530.
   PubMed Web of Science ®Google Scholar
• Das S, Ng WK, Tan RB. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci. 2012;47(1):139–151.
   PubMed Web of Science ®Google Scholar
• Vicente S, Peleteiro M, Díaz-Freitas B, et al. Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: A needle-free vaccination strategy. J Control Release. 2013;172(3):773–781.
   PubMed Web of Science ®Google Scholar
• Venturini CG, Bruinsmann FA, Contri RV, et al. Co-encapsulation of imiquimod and copaiba oil in novel nanostructured systems: promising formulations against skin carcinoma. Eur J Pharm Sci. 2015;79:36–43.
   PubMed Web of Science ®Google Scholar
• Choi MJ, Maibach HI. Elastic vesicles as topical/transdermal drug delivery systems. Int J Cosmet Sci. 2005;27(4):211–221.
   PubMedGoogle Scholar
• Zylberberg C, Matosevic S. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. Drug Deliv. 2016;23(9):3319–3329.
   PubMed Web of Science ®Google Scholar
• Fox CB, Sivananthan SJ, Duthie MS, et al. A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7. J Nanobiotechnology. 2014;12(17):10.
   PubMedGoogle Scholar
• Ma M, Wang J, Guo F, et al. Development of nanovesicular systems for dermal imiquimod delivery: physicochemical characterization and in vitro/in vivo evaluation. J Mater Sci Mater Med. 2015 Jun;26(6):191.
   PubMed Web of Science ®Google Scholar
• Zhao D, Gong T, Fu Y, et al. Lyophilized Cheliensisin A submicron emulsion for intravenous injection: characterization, in vitro and in vivo antitumor effect. Int J Pharm. 2008;357(1–2):139–147.
   PubMedGoogle Scholar
• Hanefeld A, Schmidt MV, Geissler S, et al., et al. Lyophilized nanoemulsion. U.S.A. patent US8211948B2. 2012.
   Google Scholar
• Gogoll K, Stein P, Lee KD, et al. Solid nanoemulsion as antigen and immunopotentiator carrier for transcutaneous immunization. Cell Immunol. 2016;S0008–S8749(16):30046–30056.
   Google Scholar
• Lopez PA, Denny M, Hartmann AK, et al. Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection. J Dermatol Sci. 2017;87(3):252–259.
   PubMed Web of Science ®Google Scholar
• Gerster JF, 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use. U.S.A. patent 4689338. 1983.
   Google Scholar
• Gerster JF, 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use. U.S.A. patent 4689338. 2006.
   Google Scholar
• Wick SM, Schultz HJ, Nelson GR, et al. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine. U.S.A. patent 5238944A. 1992.
   Google Scholar
• Yosha I, Tsahor H, Tikhonenko T, et al. Imiquimod cream formulation.Israel: USPTO; 2006.
   Google Scholar
• Winckle G, Osborne DW. Imiquimod formulation. U.S.A.: USPTO; 2008.
   Google Scholar
• Nordsiek MT, Balaji KS. Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream. Germany: EPO; 2010.
   Google Scholar
• Jackson JM. Composition and method for treating skin conditions. U.S.A. patent 9763930. 2017.
   Google Scholar
• Seifrath FG, Lax J. HSP for use in treatment for imiquimod related side effects. Germany patent 2928485B1. 2012.
   Google Scholar
• Gregory JJ, Nordsiek MT. Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy. U.S.A.: USPTO; 2013.
   Google Scholar
• Holldack J, Holden S, Pozzi R. Pharmaceutical compositions comprising imiquimod for use in the treatment of carcinoma in situ of the bladder. Switzerland; 2014.
   Google Scholar
• Jun S, Huidi Z, Yanting W. Liposome gel preparation capable of inhibiting scar hypertrophy and preparation and application thereof. China: EPO; 2017.
   Google Scholar
• Winckle G, Osborne DW. Imiquimod formulation. U.S.A.: IPO; 2010.
   Google Scholar
• Sen N, Gole DK. A novel process to formulate stable topical drug delivery system containing imiquimod. Mumbai: IPO; 2005.
   Google Scholar
• Bae YS, Min MK, Seong YR, et al. Method for preparing dendritic cells with capacity to induce cancer-specific immune response and pharmaceutical composition and kit incorporating dendritic cells for preventing or treating cancer or inhibiting metastasis. India: IPO; 2009.
   Google Scholar